Debra Miller is no longer serving in their board position at Exonics Therapeutics, Inc.

Jan 31, 2018
Board and Executive Moves
Background Information
Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.